Patentability of Stem Cells in the United States | Zendy

Sarah E. Fendrick | Zendy; Donald L. Zuhn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patentability of Stem Cells in the United States

Author(s) -

Sarah E. Fendrick,

Donald L. Zuhn

Publication year - 2015

Publication title -

cold spring harbor perspectives in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.853

H-Index - 105

eISSN - 2472-5412

pISSN - 2157-1422

DOI - 10.1101/cshperspect.a020958

Subject(s) - patentability , trademark , supreme court , statutory law , subject matter , stem cell , law , political science , business , law and economics , patent law , intellectual property , biology , economics , microbiology and biotechnology , curriculum

Until recently, the patentability of stem cells was well established within the judicial and statutory framework in the United States. However, the shifting landscape of patent law, particularly with regard to patent-eligible subject matter under 35 U.S.C. §101, presents new challenges to the patentability of stem cells. In this paper, we discuss the legal precedent that paved the way for stem cell patents, including Diamond v. Chakrabarty and In re Bergy. Additionally, we review recent Supreme Court cases and recent guidance issued by the U.S. Patent and Trademark Office that impose new limitations on patent-eligible subject matter and thereby threaten the patentability of stem cells in the United States.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research